- Home
- AADI vs ALVR Comparison
AADI vs ALVR Comparison
Compare AADI & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AADI
- ALVR
- Stock Information
- Founded
- AADI 2011
- ALVR 2013
- Country
- AADI United States
- ALVR United States
- Employees
- AADI N/A
- ALVR N/A
- Industry
- AADI Biotechnology: Pharmaceutical Preparations
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AADI Health Care
- ALVR Health Care
- Exchange
- AADI Nasdaq
- ALVR Nasdaq
- Market Cap
- AADI 59.4M
- ALVR 52.2M
- IPO Year
- AADI N/A
- ALVR 2020
- Fundamental
- Price
- AADI $2.34
- ALVR $0.45
- Analyst Decision
- AADI Hold
- ALVR Sell
- Analyst Count
- AADI 3
- ALVR 5
- Target Price
- AADI $1.75
- ALVR $1.00
- AVG Volume (30 Days)
- AADI 109.6K
- ALVR 344.3K
- Earning Date
- AADI 11-06-2024
- ALVR 11-12-2024
- Dividend Yield
- AADI N/A
- ALVR N/A
- EPS Growth
- AADI N/A
- ALVR N/A
- EPS
- AADI N/A
- ALVR N/A
- Revenue
- AADI $25,070,000.00
- ALVR N/A
- Revenue This Year
- AADI $9.39
- ALVR N/A
- Revenue Next Year
- AADI $6.15
- ALVR N/A
- P/E Ratio
- AADI N/A
- ALVR N/A
- Revenue Growth
- AADI 7.80
- ALVR N/A
- 52 Week Low
- AADI $1.21
- ALVR $0.40
- 52 Week High
- AADI $2.63
- ALVR $2.45
- Technical
- Relative Strength Index (RSI)
- AADI 58.75
- ALVR 31.87
- Support Level
- AADI $2.25
- ALVR $0.40
- Resistance Level
- AADI $2.45
- ALVR $0.53
- Average True Range (ATR)
- AADI 0.11
- ALVR 0.04
- MACD
- AADI -0.01
- ALVR 0.00
- Stochastic Oscillator
- AADI 39.89
- ALVR 27.34
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.